Abstract
For health technology assessment (HTA) bodies that make reimbursement decisions, real-world evidence (RWE) is becoming more important in understanding lifelong diseases like multiple sclerosis (MS), as randomized controlled trials provide limited insights in the short term. RWE includes data from sources such as registries, observational studies and electronic health records. This analysis aims to assess the value of RWE in recent HTA appraisals for MS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
